Does Cannabidiol Have a Benefit as a Supportive Care Drug in Cancer?

Lord, S; Hardy, J; Good, P

Does Cannabidiol Have a Benefit as a Supportive Care Drug in Cancer?

Lord, S Hardy, J Good, P

Permalink

Publisher:: Springer Nature
Publication Type:: Journal Article
Citation:: Curr Treat Options Oncol, 2022, 23, (4), pp. 514-525
Issue Date:: 2022-04

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download full textAdobe PDF (252.57 kB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Lord, S
dc.contributor.author	Hardy, J
dc.contributor.author	Good, P https://orcid.org/0000-0002-8198-0375
dc.date.accessioned	2023-05-30T02:13:21Z
dc.date.available	2021-09-27
dc.date.available	2023-05-30T02:13:21Z
dc.date.issued	2022-04
dc.identifier.citation	Curr Treat Options Oncol, 2022, 23, (4), pp. 514-525
dc.identifier.issn	1527-2729
dc.identifier.issn	1534-6277
dc.identifier.uri	http://hdl.handle.net/10453/170544
dc.description.abstract	Cannabinoids have been purported as having a wide range of therapeutic uses although currently, there is minimal evidence to support these claims. Patients with advanced cancer experience many distressing symptoms, with some turning to medicinal cannabis to help alleviate these. Focus has fallen on cannabidiol (CBD) as a potential treatment for a variety of symptoms in advanced cancer due to the lack of psychoactive side effects and the potential molecular mechanisms of action associated with this cannabinoid. Many cannabinoid products are easily available in the community, and more countries are legalizing or allowing over the counter products. Studies show that CBD is generally well tolerated, but there are many potential drug interactions that have not been well studied. Few studies have specifically looked at the role of CBD in treating cancer symptoms, with most focusing on combination cannabinoid products. There are currently many unknowns associated with CBD, including which symptoms it might be best for, appropriate dosing, and route of administration. This is especially important in advanced cancer where patients often have significant organ dysfunction and frailty that could impact on the pharmacology of CBD. A small pilot study has shown promise for a role of CBD in the psychological symptoms associated with advanced cancer. Further research is currently underway to further clarify the role of CBD in this setting and to understand how best it might help our patients. Currently we advocate that CBD be used in supervised clinical trials, so that efficacy and adverse effects can be closely monitored.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	Springer Nature
dc.relation.ispartof	Curr Treat Options Oncol
dc.relation.isbasedon	10.1007/s11864-021-00934-0
dc.rights	info:eu-repo/semantics/openAccess
dc.subject.classification	Oncology & Carcinogenesis
dc.subject.mesh	Cannabidiol
dc.subject.mesh	Cannabinoids
dc.subject.mesh	Dronabinol
dc.subject.mesh	Humans
dc.subject.mesh	Neoplasms
dc.subject.mesh	Pharmaceutical Preparations
dc.subject.mesh	Pilot Projects
dc.subject.mesh	Humans
dc.subject.mesh	Neoplasms
dc.subject.mesh	Cannabinoids
dc.subject.mesh	Cannabidiol
dc.subject.mesh	Pharmaceutical Preparations
dc.subject.mesh	Pilot Projects
dc.subject.mesh	Dronabinol
dc.subject.mesh	Cannabidiol
dc.subject.mesh	Cannabinoids
dc.subject.mesh	Dronabinol
dc.subject.mesh	Humans
dc.subject.mesh	Neoplasms
dc.subject.mesh	Pharmaceutical Preparations
dc.subject.mesh	Pilot Projects
dc.title	Does Cannabidiol Have a Benefit as a Supportive Care Drug in Cancer?
dc.type	Journal Article
utslib.citation.volume	23
utslib.location.activity	United States
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Faculty of Health/IMPACCT
utslib.copyright.status	open_access	*
dc.date.updated	2023-05-30T02:13:19Z
pubs.issue	4
pubs.publication-status	Published
pubs.volume	23
utslib.citation.issue	4

Abstract:

Cannabinoids have been purported as having a wide range of therapeutic uses although currently, there is minimal evidence to support these claims. Patients with advanced cancer experience many distressing symptoms, with some turning to medicinal cannabis to help alleviate these. Focus has fallen on cannabidiol (CBD) as a potential treatment for a variety of symptoms in advanced cancer due to the lack of psychoactive side effects and the potential molecular mechanisms of action associated with this cannabinoid. Many cannabinoid products are easily available in the community, and more countries are legalizing or allowing over the counter products. Studies show that CBD is generally well tolerated, but there are many potential drug interactions that have not been well studied. Few studies have specifically looked at the role of CBD in treating cancer symptoms, with most focusing on combination cannabinoid products. There are currently many unknowns associated with CBD, including which symptoms it might be best for, appropriate dosing, and route of administration. This is especially important in advanced cancer where patients often have significant organ dysfunction and frailty that could impact on the pharmacology of CBD. A small pilot study has shown promise for a role of CBD in the psychological symptoms associated with advanced cancer. Further research is currently underway to further clarify the role of CBD in this setting and to understand how best it might help our patients. Currently we advocate that CBD be used in supervised clinical trials, so that efficacy and adverse effects can be closely monitored.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/170544